The short version of peptide backbone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| 分子类别 | 合成多肽 | 含非天然氨基酸与脂肪酸侧链 |
| 分子量 | 约 4.7 kDa | 多肽量级，精确值随计法而异 |
| 外观 | 白色至类白色冻干粉 | 常见冻干形态，供复溶使用 |
| 溶解性 | 易溶于水 | 复溶后为澄清至微乳光液体 |
| 常见同义词 | LY3437943 | 开发阶段使用的代号 |
Retatrutide is handled in laboratories mainly as a lyophilized solid for analytical and biochemical research. The peptide is typically supplied as a white to off-white powder and is reconstituted in appropriate solvents before use. Because peptide-based molecules are sensitive to temperature, moisture, and repeated freeze-thaw cycles, proper storage conditions affect both stability and measurement accuracy. Laboratories generally follow documented handling procedures to maintain the integrity of the material across experiments.
Identification and purity assessment rely on established analytical techniques. Reverse-phase high-performance liquid chromatography separates the compound from related impurities and degradation products. Mass spectrometry confirms molecular identity and detects modifications that change the expected mass. Additional methods such as amino acid analysis or capillary electrophoresis may be used for verification. Small differences in sample preparation can influence results, so procedures are usually controlled and documented in detail. Consistency between runs supports confidence in reported values.
Stability studies examine how the molecule changes under defined conditions of temperature, humidity, and light exposure over time. Results are used to set storage recommendations and shelf-life limits. In practice, lyophilized peptide material is often stored at low temperatures to slow degradation, while reconstituted solutions are handled more carefully because they are generally less stable. Reported stability data apply to specific formulations and conditions, so extrapolation to other preparations requires caution.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Silica coatings increase the external surface area to assist in binding and are heat resistant. There are various coatings used to prevent leaching of the magnetic core of the nanoparticles; these coatings have a significant salt concentration with a slightly alkaline (basic) pH. Polyethylene glycol (PEG) is an example of a hydrophilic coating that has been used as a biocompatible targeting modality. Hydrophilic PEG interacts beneficially with the physiological environment to improve biocompatibility by preventing opsonization on the surface of the particles, thus increasing circulation time from minutes to hours, or even days, for magnetic nanoparticles. MRI shows prolonged PEG circulation and increased SPIO-PEG-D particle accumulation within the tumor with magnetic guidance. Coating not only provides hydrophilic and hydrophobic properties but can also contribute to temperature- and pH-dependent properties. Particular substances, such as PNG, provide these two properties, allowing unique and efficient delivery of drugs. This also enables greater control of release, as body temperature allows a greater amount of drug released, while physiological pH allows a lower amount of drug released. Other coating options for similar pH-dependent properties include the hydrogel chitosan that is crosslinked to a polymer coating. These coating choices have displayed positive results in delivery of anticancer drugs.
== Availability == There are two types of isobaric tags commercially available: tandem mass tags (TMT) and isobaric tags for relative and absolute quantitation (iTRAQ). Amine-reactive TMT are available in duplex, 6-plex 10-plex, and now 11-plex sets. Amine-reactive iTRAQ are available in 4-plex and 8-plex forms.
=== Dutch === Dutch, like many Germanic languages, is capable of forming compounds of potentially limitless length. The 49-letter word Kindercarnavalsoptochtvoorbereidingswerkzaamheden, meaning "preparation activities plan for a children's carnival procession", was cited by the 1996 Guinness Book of World Records as the longest Dutch word. The longest word in the authoritative Van Dale Dutch dictionary (2009 edition) in plural form is meervoudigepersoonlijkheidsstoornissen; 38 letters long, meaning "multiple personality disorders". The entry in the dictionary however is in the singular, counting 35 letters. The free OpenTaal dictionary, which has been certified by the Dutch Language Union (the official Dutch language institute) and is included in many open-source applications, contains the following longest words, which are 40 letters long:
In materials science and molecular biology, thermostability is the ability of a substance to resist irreversible change in its chemical or physical structure, often by resisting decomposition or polymerization, at a high relative temperature. Thermostable materials may be used industrially as fire retardants. A thermostable plastic, an uncommon and unconventional term, is likely to refer to a thermosetting plastic that cannot be reshaped when heated, than to a thermoplastic that can be remelted and recast. Thermostability is also a property of some proteins. To be a thermostable protein means to be resistant to changes in protein structure due to applied heat.
Sources: en.wikipedia.org
== Management == Fever does not necessarily need to be treated, and most people with a fever recover without specific medical attention. Although it is unpleasant, fever rarely rises to a dangerous level even if untreated. In cases of hyperthermia, damage to the brain generally does not occur until the temperature reaches 40.0 °C (104.0 °F). Treating fever in people with sepsis does not affect outcomes. Small trials have shown no benefit of treating fevers of 38.5 °C (101.3 °F) or higher of critically ill patients in ICUs, and one trial was terminated early because patients receiving aggressive fever treatment were dying more often. According to the NIH, the two assumptions which are generally used to argue in favor of treating fevers have not been experimentally validated. These are that (1) a fever is noxious, and (2) suppression of a fever will reduce its noxious effect. Most of the other studies supporting the association of fever with poorer outcomes have been observational in nature. In theory, these critically ill patients and those faced with additional physiologic stress may benefit from fever reduction, but the evidence on both sides of the argument appears to be mostly equivocal.
=== Stretch receptors === Stretch receptors have two parts: Spindle cells and Golgi tendons. Spindle cells, located in the center of a muscle, send messages for the muscle to contract. On the other hand, Golgi tendon receptors are located near the end of a muscle fiber and send messages for the muscle to relax. As these receptors are trained through continual use, stretching becomes easier. When reflexes that inhibit flexibility are released the splits then become easier to perform. The splits use the body's complete range of motion and provide a complete stretch.
Sinfield, who now favoured a softer approach, took lyrical inspiration from Homer's Odyssey, musical inspiration from jazz players like Miles Davis and Ahmad Jamal, and a trip to the Balearic Islands. Islands featured the instrumental "Sailor's Tale", with a droning Mellotron and Fripp's banjo-inspired guitar solo; the raunchy blues-rocker "Ladies of the Road", a tribute to groupies that featured Wallace and Collins singing Beatlesque backing vocals; and "Song of the Gulls", which was developed from the instrumental "Suite No. 1" from Giles, Giles & Fripp's 1968 album and would be the only time the band would utilize an orchestra. Burrell disliked Sinfield's lyrics, and one of the band members allegedly called Islands "an airy-fairy piece of shit". Released in December 1971, Islands charted at No. 30 in the UK and No. 76 in the US. That same month, the band undertook a short tour of the United States, after which Fripp informed Sinfield that he could no longer work with him and asked him to leave King Crimson. In January 1972, the remaining four members broke up acrimoniously in rehearsals, owing partially to Fripp's refusal to play a composition by Collins. He later cited this as "quality control", with the idea that King Crimson would perform the "right" kind of music. In order to fulfill touring contracts in the United States in 1972, Fripp, Collins, Burrell, and Wallace reformed with the intention of disbanding immediately after the tour. Recordings from various North American dates during January and February 1972 were released as Earthbound in June of that year.
Sources: en.wikipedia.org
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。
天然肽类在体内容易被酶解并快速清除。脂肪酸侧链与非天然氨基酸可以延缓清除、降低酶解速率。修饰后的分子因此更适合较长间隔的给药安排。
公开资料主要来自临床阶段的报告与注册平台记录。这些材料提供的是阶段性信息，而非最终结论。完整的安全性与有效性数据仍在积累中。
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.